Navigation Links
Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder

Phase 3 trials conducted on Remicade (infliximab) showed rapid, significant improvement in patients with moderate to severe plaque psoriasis. The stud mainly used placebo-// control and dose-ranging from 3 mg/kg and 5 mg/kg. The continuous eight week maintenance therapy resulted in greater long-term skin clearance compared with as-needed therapy regimens within each dose.

At 10 weeks it was seen that 70 % of the patients treated with Remicade 3 mg/kg and 75 % of patients receiving 5 mg/kg achieved at least 75 % improvement in psoriasis. The measurement scale used was Psoriasis Area Severity Index (PASI 75). At the end of the 50 weeks patients receiving Remicade 5 mg/kg every eight-week maintenance therapy saw the highest level of improvement. The results were presented at the 64th annual American Academy of Dermatology meeting.

Alan Menter, MD, chairman, Division of Dermatology, Baylor University Medical Center, and lead study investigator said that patients receiving scheduled Remicade maintenance therapy achieved long-term cure against psoriasis, a lifelong, chronic inflammatory disease. Statistics show that nearly two million Americans suffer from this disease.

Robert Matheson, MD, Oregon Medical Research Center, and study investigator said that Remicade in the treatment of a disease offers great physical and emotional challenges. It has a potential to result in complete skin clearance.

The United States Food and Drug Administration (FDA) accepted the use of Remicade in the treatment of moderate to severe plaque psoriasis. Hence the European Commission also approved Remicade for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to other systemic therapy.


'"/>




Page: 1

Related medicine news :

1. Remicade Therapy Effective in Treating Severe Psoriasis
2. Sanitation Emerges as the Winner
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Treatment for Menieres disease
6. Treatment for pre-menstrual syndrome is ineffective
7. Better Treatment for obesity
8. Gene Treatment for Heart Disease
9. More People Seeking Treatment for Depression
10. Focused Treatment For Childhood Cancer
11. Inadequate Drug Treatment For Youth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... ... 24, 2017 , ... The health insurance industry is an ... and the Open Enrollment Period (OEP). 2016 was no exception. If anything, it ... higher deductibles, rising premiums, and few choices with their insurance, which is a ...
(Date:1/24/2017)... ... 2017 , ... i2i Population Health, a national leader in population health management ... “Cary’s broad financial background is an excellent fit for i2i,” says Justin Neece, president. ... skills we need to take the company to the next level of growth.” ...
(Date:1/24/2017)... ... January 24, 2017 , ... Learn to use popular brainwave and ... in relationships. Course offered by Dr. Carol Francis at PVNET on Sundays in ... and the many hands-on experiences. , Dr. Carol Francis shows business owners, ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health ... annual Solutions Series of webinars will start January 31 with a session about ... of current health and benefits topics, including employee engagement, pricing transparency, population health ...
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader ... of medical experts. In his new role Dr. Dobke will provide physician oversight for ... Dobke is the Head of Plastic Surgery and Associate Professor of Surgery at UC ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... January 24, 2017 Analysis of the Liquid ... Liquid Biopsies - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover How ...
(Date:1/24/2017)... , and GAITHERSBURG, Md. , Jan. ... XON ), a leader in the engineering and industrialization of ... the planet, today announced that it has entered into a ... GNVC ), a clinical-stage company and pioneer in the ... intends to integrate and expand upon GenVec,s expertise in adenoviral ...
(Date:1/24/2017)... 2017   Keneric Healthcare , a medical ... patient care products, today announced their partnership with ... reach of both companies by leveraging their clinical ... Angelini Pharma Inc . is ... Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal).  RTD™ wound ...
Breaking Medicine Technology: